Marshall Wace, LLP Halozyme Therapeutics, Inc. Transaction History

Marshall Wace, LLP

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 15, 2024	SELL	$33.68 - $41.95 $19.2 Million - $23.9 Million	-570,635 Reduced 88.31%	75,533 $3.07 Million
Q4 2023 Feb 14, 2024	SELL	$33.32 - $42.1 $69.3 Million - $87.5 Million	-2,078,643 Reduced 76.29%	646,168 $23.9 Million
Q3 2023 Nov 14, 2023	BUY	$36.46 - $44.03 $14.6 Million - $17.7 Million	401,288 Added 17.27%	2,724,811 $104 Million
Q2 2023 Aug 14, 2023	BUY	$30.28 - $38.74 $43.4 Million - $55.5 Million	1,433,856 Added 161.17%	2,323,523 $83.8 Million
Q1 2023 May 15, 2023	BUY	$32.86 - $55.7 $29.2 Million - $49.6 Million	889,667 New	889,667 $34 Million
Q2 2022 Aug 15, 2022	BUY	$37.35 - $48.3 $4.14 Million - $5.35 Million	110,861 New	110,861 $4.88 Million
Q1 2020 May 15, 2020	SELL	$13.9 - $21.83 $115,606 - $181,560	-8,317 Closed	0 $0
Q4 2019 Feb 14, 2020	BUY	$14.93 - $19.53 $124,172 - $162,431	8,317 New	8,317 $147,000
Q3 2019 Nov 14, 2019	SELL	$15.2 - $17.69 $7.8 Million - $9.08 Million	-513,083 Closed	0 $0
Q2 2019 Aug 14, 2019	BUY	$14.75 - $17.26 $6.89 Million - $8.06 Million	467,136 Added 1016.68%	513,083 $8.82 Million
Q1 2019 May 14, 2019	BUY	$13.94 - $17.58 $640,501 - $807,748	45,947 New	45,947 $740,000

543

125M

294K

180K

Ticker HALO
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 139,288,992
Market Cap $6.62B
Description
Halozyme Therapeutics, Inc. operates as a biopharma technology platform company in the United States, Switzerland, Ireland, Belgium, Japan, and internationally. The company's products are based on the ENHANZE drug delivery technology, a patented recombinant human hyaluronidase enzyme (rHuPH20) that enables the subcutaneous delivery of injectable...

Get notified when there are updates to the investment portfolio of Marshall Wace, LLP, based on Form 13F filings with the SEC.

Stay updated on Marshall Wace, LLP with notifications on news.